glp-1 agonists for obesity In Non-Diabetic Patients: Game Changer Or Overhyped? A Critical Analysis GlobalRPH GLP-1 Agonists In Obesity

2024;7(3):e489

[DOI] [PubMed] [Google Scholar] 132.DeVries JH, Bain SC, Rodbard HW, Seufert J, D'Alessio D, Thomsen AB, Zychma M, Rosenstock J Liraglutide-Detemir Study Group

AC, active comparator

[DOI] [PubMed] [Google Scholar] 52.Yamada Y., Katagiri H., Hamamoto Y., Deenadayalan S., Navarria A., Nishijima K., Seino Y., PIONEER 9 Investigators Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): A 52-week, phase 2/3a, randomised, controlled trial

GLP-1 Mechanism and Its Specific Impact on IBD Pathophysiology GLP-1 agonists work by enhancing insulin secretion, slowing gastric emptying, and activating GLP-1 receptors throughout the GI tract

We could hypothesize that maintaining the exercise could lead to a virtuous cycle of positive feelings and behaviors